Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.
You may also be interested in...
Nile’s Natriuretic Peptide Helps Heart, Spares Kidney
Phase IIa data suggest CD-NP won’t have bad effects that dogged similar drugs.
Nile’s Natriuretic Peptide Helps Heart, Spares Kidney
Phase IIa data suggest CD-NP won’t have bad effects that dogged similar drugs.
Scios Natrecor Outcomes Study Is Expected To Begin Enrollment In 2007
The Johnson & Johnson subsidiary will begin enrollment more than a year after an independent panel recommended the study.